SCHEMBL3578426

SCHEMBL3578426

CCOC(=O)CC(c1cccc(OS(C)(=O)=O)c1)C(N)C(=O)OCc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
F10 P00742 3/20 0.41
PPARG P37231 2/20 0.39
SLC15A1 P46059 2/20 0.39
PPARA Q07869 1/20 0.38
F2 P00734 3/20 0.36
FAAH O00519 1/20 0.36
FFAR1 O14842 2/20 0.35
CYP2D6 P10635 1/20 0.35
SLC6A2 P23975 1/20 0.35
SLC6A4 P31645 1/20 0.35
SLC6A3 Q01959 1/20 0.35
KCNH2 Q12809 1/20 0.35
PRSS1 P07477 1/20 0.35
ADRB2 P07550 1/20 0.34
ADRB3 P13945 1/20 0.34
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1822877 0.95 KMT2A (0.45) KMT2ASMN1; SMN2PPARGSLC15A1PPARA
SCHEMBL1825670 0.91 KMT2A (0.43) KMT2ASMN1; SMN2SLC15A1FAAHADRB2
SCHEMBL1824782 0.90 SMN1; SMN2 (0.41) KMT2ASMN1; SMN2F10SLC15A1F2
SCHEMBL1826721 0.89 KMT2A (0.42) KMT2ASMN1; SMN2PPARGSLC15A1FAAH
SCHEMBL1824127 0.89 PPARG (0.45) F10PPARGSLC15A1PPARAF2
SCHEMBL1828934 0.89 KMT2A (0.41) KMT2ASMN1; SMN2PPARGSLC15A1PPARA
SCHEMBL1825487 0.88 LMNA (0.41) KMT2ASMN1; SMN2F10SLC15A1
SCHEMBL3572878 0.87 KMT2A (0.41) KMT2ASMN1; SMN2PPARGSLC15A1PPARA
SCHEMBL1824554 0.86 F10 (0.42) KMT2ASMN1; SMN2F10PPARGSLC15A1
SCHEMBL1829066 0.86 KMT2A (0.43) KMT2ASMN1; SMN2PPARGPPARAFAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7714157-B2 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-05-11 US disclosed
US-20070270603-A1 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED 2007-11-22 US disclosed
US-7271280-B2 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-09-18 US disclosed
EP-1481967-A1 PROCESS FOR THE PREPARATION OF BIARYL COMPOUNDS Sumitomo Chemical Company, Limited (JP) 2004-12-01 EP disclosed
US-20040158093-A1 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040158093-A1 Process for preparing a biaryl compound CYP1B1, REL, CYP2F1 KMT2A 1068/4885SMN1; SMN2 2274/4885F10 1460/4885
US-20070270603-A1 Process for preparing a biaryl compound CYP4A11, CYP4B1, CYP51A1 KMT2A 1084/4885SMN1; SMN2 3216/4885F10 1977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.